|Dr. Engelbert Coster Tjeenk Willink M.D.||Chairman of Exec. Board & CEO||N/A||N/A||56|
|Dr. Bernhard Duettmann||CFO & Member of Exec. Board||N/A||N/A||57|
|Dr. Barthold Piening||Chief Technical Operations Officer & Member of Exec. Board||N/A||N/A||59|
|Ms. Leslie Isabelle Iltgen||VP of Investor Relations||N/A||N/A||N/A|
|Mr. Sebastian Kramer-Bach||Exec. VP of Corp. Communication||N/A||N/A||42|
STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications. The Branded Products segment offers APO-Go a Parkinsons medicine; Aqualor for rhinitis/sore throat; Grippostad a cold medicine; Snup for rhinitis; and Vitaprost for prostate disease indications, as well as Ladival a sun protection product. The company is also involved in the wholesale activities in the pharmaceutical market. It serves patients and consumers, doctors, pharmacies and pharmacy chains, hospitals, mail-order companies, buying groups, wholesalers, and other service providers in the health care market, as well as public or private health insurance organizations. STADA Arzneimittel Aktiengesellschaft was founded in 1895 and is headquartered in Bad Vilbel, Germany.
STADA Arzneimittel Aktiengesellschaft’s ISS Governance QualityScore as of July 1, 2017 is 2. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 1; Compensation: 7.